Sandoz Will Differentiate To Serve A Different World
Executive Summary
A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.
You may also be interested in...
Global Top Three Trade Places As Going Gets Tough, Especially In The US
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.
US And Japan Cause A Slip In Value-Added Market
Difficulties in the US and Japan have stalled growth in the global value-added medicines market. But a coming wave of digital therapeutics promises to revive the market.
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.